Showing results (181-190 of 261) with videos related to
Sort By:
Pageof 27
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2011
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantationCaron A Jacobson, Amin T Turki, Sean M McDonough, et al.Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.JCI Insight|November 5, 2016
Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cellsMasahiro Hirakawa, Tiago R Matos, Hongye Liu, et al.Open Forum Infectious Diseases|August 31, 2022
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid MalignanciesAmy C Sherman, Jennifer L Crombie, ChiAn Cheng, et al.British Journal of Haematology|January 6, 2016
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialPhilippe Armand, Haesook T Kim, Marie-Michele Sainvil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeMargaretha G M Roemer, Ranjana H Advani, Azra H Ligon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 StudyRadhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell LymphomaEdward R Scheffer Cliff, Guido D Pelaez, Fei Wan, et al.The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.Pageof 27